Despite the deceleration in revenue growth (+7.7%), the adjusted EBIT margin snowballed 25.5% in Q2, benefiting from an improvement in the product mix, a favourable currency environment and effective cost management. As the recently-launched products have the potential to put the business back on track, the revenue guidance has been reiterated. Given the robust development in earnings in H1, the FY18/19 EBIT guidance has been upgraded.
06 May 2019
Profitability guidance upgrade overshadows revenue deceleration
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Profitability guidance upgrade overshadows revenue deceleration
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
06 May 2019 -
Author:
Sumit Sayal -
Pages:
3
Despite the deceleration in revenue growth (+7.7%), the adjusted EBIT margin snowballed 25.5% in Q2, benefiting from an improvement in the product mix, a favourable currency environment and effective cost management. As the recently-launched products have the potential to put the business back on track, the revenue guidance has been reiterated. Given the robust development in earnings in H1, the FY18/19 EBIT guidance has been upgraded.